Source: Morningstar
CDT Equity Inc., a biopharmaceutical development company, has entered into an evaluation agreement with Manoira Corporation, a specialty Animal Health company, to explore potential improvements to Manoira’s upcoming product portfolio. The collaboration will assess CDT’s clinical-stage compounds AZD1656, including proprietary cocrystal derivatives, and AZD5904 for their ability to enhance product efficacy, safety, formulation, and other commercially relevant characteristics.
Manoira plans to introduce its first Animal Health products during the first quarter of 2027, using licensed, patented cannabinoid cocrystal and solid-form technologies. The products are currently undergoing manufacturing and testing, with the company targeting underserved areas of animal healthcare.
If evaluations demonstrate promising results, the companies intend to pursue licensing and commercialization agreements. The partnership could allow CDT to expand the applications of its existing pharmaceutical assets into the Animal Health market, potentially benefiting companion animals and livestock while creating new commercial opportunities through strategic collaboration and scientific innovation.
Read the full story HERE: https://www.morningstar.com/news/globe-newswire/9853877/cdt-partners-with-manoira-to-explore-enhancing-animal-health-products-ahead-of-launch